Online inquiry

IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3952MR)

This product GTTS-WQ3952MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&FCRL5 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_000733.4; NM_001195388.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 83416
UniProt ID P07766; Q96RD9
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3952MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15571MR IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA UNII-FFX71LCS5T
GTTS-WQ2318MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ALXN6000
GTTS-WQ5212MR IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CAT-8015
GTTS-WQ10616MR IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY3300054
GTTS-WQ11912MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MLN-1202
GTTS-WQ5148MR IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CAN34D3-65
GTTS-WQ957MR IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-323
GTTS-WQ15103MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ST2146
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW